GSK3B and central nervous system cancer: The proto-oncogene AEG-1, overexpressed in gliomas, is targeted to GSK-3β (glycogen synthase kinase-3β) to activate the Wnt/β-catenin pathway, mediating a pro-tumor phenotypic shift in microglia and reducing the sensitivity of glioma cells to TMZ (88).